Cascadian Therapeutics
Seattle
About Cascadian Therapeutics
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $64.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2016)
- Ticker: nasdaq:CASC
- Website: cascadianrx.com
- Phone: +1 206.801.2100
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cascadian-therapeutics-3096289 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.